TD Asset Management Inc Has $648.81 Million Stake in AbbVie Inc. $ABBV

TD Asset Management Inc cut its stake in shares of AbbVie Inc. (NYSE:ABBV) by 34.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,578,333 shares of the company’s stock after selling 1,341,743 shares during the quarter. TD Asset Management Inc owned approximately 0.15% of AbbVie worth $648,812,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ABBV. ACT Advisors LLC. raised its position in shares of AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after acquiring an additional 41 shares during the last quarter. Willner & Heller LLC boosted its holdings in AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock valued at $1,472,000 after acquiring an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC boosted its holdings in AbbVie by 3.1% in the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock valued at $359,000 after acquiring an additional 43 shares during the last quarter. Leslie Global Wealth LLC increased its position in AbbVie by 1.5% during the 2nd quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company’s stock valued at $751,000 after purchasing an additional 44 shares during the period. Finally, Bank of Jackson Hole Trust increased its position in AbbVie by 0.6% during the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after purchasing an additional 44 shares during the period. Institutional investors own 70.23% of the company’s stock.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on ABBV shares. Royal Bank Of Canada boosted their price target on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Bank of America increased their price objective on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Morgan Stanley reissued an “overweight” rating and set a $296.00 target price on shares of AbbVie in a research note on Monday, August 3rd. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Finally, UBS Group upped their price target on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $275.95.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New lung-cancer data supports AbbVie’s long-term growth strategy. At the 2026 World Conference on Lung Cancer, AbbVie presented clinical, translational and real-world data for investigational programs including ABBV-1480, telisotuzumab adizutecan and ABBV-706 across non-small cell and small cell lung cancer. The updates highlight potential future oncology revenue sources beyond the company’s established immunology portfolio. AbbVie WCLC 2026 announcement
• Positive Sentiment: AbbVie is broadening its aesthetics pipeline. The company has initiated a Phase 2 study evaluating a treatment for forehead lines, adding another potential product to its aesthetics franchise and reinforcing efforts to diversify growth. AbbVie aesthetics pipeline update
• Neutral Sentiment: AbbVie’s relatively low market correlation reflects its defensive pharmaceutical revenue base. Investor performance is driven more by product demand, reimbursement and payer dynamics than by broad equity-market movements. This may help explain the stock’s resilience, but the article does not identify a new earnings catalyst. What Moves AbbVie Stock
• Neutral Sentiment: AbbVie recently reported quarterly EPS and revenue above consensus, with revenue rising 10.2% year over year, and guided to third-quarter EPS of $3.84–$3.88. Analysts’ average price target of $275.73 remains above the current trading level, although the stock’s elevated valuation raises expectations. AbbVie stock and earnings information
• Negative Sentiment: An early end to a long-term emraclidine schizophrenia study introduces uncertainty. Investors may question the implications for AbbVie’s neuroscience pipeline and the program’s development prospects until the company provides additional details. AbbVie emraclidine study update
• Negative Sentiment: An executive vice president sold approximately $8.18 million of ABBV shares, reducing his position by about 30.5%. The sale may weigh modestly on sentiment, although insider transactions can reflect personal financial planning rather than a change in business outlook. AbbVie insider sale

AbbVie Stock Performance

Shares of ABBV opened at $265.62 on Friday. The firm has a market cap of $469.29 billion, a PE ratio of 75.03, a price-to-earnings-growth ratio of 0.88 and a beta of 0.30. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The business’s 50 day moving average price is $248.48 and its two-hundred day moving average price is $227.49.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts predict that AbbVie Inc. will post 14.06 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.